| Literature DB >> 23692985 |
Giovanni Almanzar1, Manuela Zlamy, Christian Koppelstaetter, Andrea Brunner, Verena Jeller, Christina Duftner, Christian Dejaco, Juergen Brunner, Martina Prelog.
Abstract
INTRODUCTION: Juvenile idiopathic arthritis is a heterogeneous T cell-mediated autoimmune disease with symptoms of premature aging of the immune system (immunosenescence). The present work is an investigation of immunosenescence parameters, such as quantity of naive and CD28- T cells, T cell receptor excision circles, relative telomere length and alterations of peripheral T cell replication, and was performed via comparison of a case of acute exacerbation of juvenile idiopathic arthritis against six patients with juvenile idiopathic arthritis with disease remission and six age-matched healthy donors over a follow-up course of 12 months. CASEEntities:
Year: 2013 PMID: 23692985 PMCID: PMC3686624 DOI: 10.1186/1752-1947-7-135
Source DB: PubMed Journal: J Med Case Rep ISSN: 1752-1947
Matching of the juvenile idiopathic arthritis (JIA) group (patients 1 to 6), our patient with JIA with acute exacerbation (patient 7), and healthy donors (patients 8 to 13)
| 1 | 191 | 44 | 147 |
| 2 | 143 | 44 | 99 |
| 3 | 161 | 37 | 124 |
| 4 | 157 | 61 | 96 |
| 5 | 196 | 42 | 154 |
| 6 | 173 | 49 | 124 |
| 7 | 192 | 48 | 144 |
| 8 | 184 | - | - |
| 9 | 136 | - | - |
| 10 | 156 | - | - |
| 11 | 144 | - | - |
| 12 | 204 | - | - |
| 13 | 172 | - | - |
T cell subset counts in patients with juvenile idiopathic arthritis (JIA) and healthy donors (HD)
| CD3+ | 1.1/1.3 | 1.73±0.68 (1.60; 1.10 to 2.80) | 1.04±0.49 (0.98; 0.51 to 1.72)++ | 2.18±0.36 (2.0; 1.90 to 2.70) |
| CD3+HLA-DR+ | 0.06/0.03 | 0.09±0.01 (0.09; 0.08 to 0.11) | 0.09±0.05 (0.11; 0.03 to 0.16) | 0.13±0.03 (0.12; 0.11 to 0.19)xx |
| CD3+CD4+ | 0.72/0.93 | 0.94±0.48 (0.79; 0.55 to 1.83) | 0.59±0.31 (0.62; 0.24 to 0.96)++ | 1.31±0.35 (1.24; 0.88 to 1.84) |
| CD4+CD25+CD62L+ | 0.12/0.04 | 0.19±0.18 (0.15; 0.03 to 0.52) | 0.14±0.09 (0.13; 0.05 to 0.26) | 0.25±0.08 (0.23; 0.15 to 0.35) |
| CD4+CD28+ | 0.20/0.31 | 0.90±0.46 (0.76; 0.53 to 1.73)*** | 0.57±0.29 (0.62; 0.23 to 0.90)+++ | 1.27±0.34 (1.22; 0.84 to 1.78)xx |
| CD4+CD28+CD45RA+ | 0.15/0.16 | 0.33±0.24 (0.25; 0.001 to 0.62) | 0.31±0.15 (0.35; 0.13 to 0.46)++ | 0.49±0.012 (0.45; 0.34 to 0.63)xx |
| CD4+CD45RA+CD62L+ | 0.22/0.04 | 0.39±0.24 (0.43; 0.001 to 1.14) | 0.19±0.08 (0.19; 0.09 to 0.28) | 0.34±0.32 (0.16, 0.19 to 0.61) |
| CD4+CD45RO+ | 0.12/0.15 | 0.08±0.07 (0.06; 0.01 to 0.22) | 0.22±0.13 (0.23; 0.07 to 0.38) | 0.15±0.11 (0.17; 0.001 to 0.29) |
| CD3+CD8+ | 0.34/0.37 | 0.50±0.19 (0.49; 0.27 to 0.73) | 0.41±0.18 (0.37; 0.21 to 0.65)++ | 0.78±0.14 (0.76; 0.63 to 0.96) |
| CD8+CD28+ | 0.28/0.32 | 0.41±0.16 (0.41; 0.18 to 0.64) | 0.31±0.15 (0.26; 0.17 to 0.51)++ | 0.61±0.11 (0.64; 0.47 to 0.75) |
| CD8+CD28+CD45RA+ | 0.30/0.25 | 0.57±0.51 (0.43; 0.01 to 1.44) | 0.29±0.13 (0.27; 0.16 to 0.47)+ | 0.66±0.24 (0.63; 0.41 to 1.06) |
| CD8+CD45RA+CD62L+ | 0.07/0.09 | 0.31±0.25 (0.20; 0.05 to 0.53)*** | 0.19±0.07 (0.16; 0.12 to 0.29) | 0.32±0.29 (0.13; 0.19 to 0.52) |
| CD8+CD45RO+ | 0.38/0.90 | 0.23±0.12 (0.23; 0.03 to 0.41)** | 0.70±0.30 (0.61; 0.30 to 1.13) | 0.41±0.25 (0.42; 0.001 to 0.69) |
Total counts ×103 cells/μL are given as mean±standard deviation (median; range). Significant differences between patients with JIA (JIA group) and JIA follow-up are indicated with **p<0.025, ***p<0.01. Significant differences between JIA follow-up and HD are indicated with +p<0.05, ++p<0.025, +++p<0.01. Significant differences between JIA group and HD are indicated with xxp<0.025.
Figure 1Lower naive T cell counts in patients with Juvenile Idiopathic Arthritis (JIA). Lower CD4+CD28+CD45RA+ (A) and CD4+CD28+ T cell counts (B) in patients with JIA are shown. Closed squares show patients with juvenile idiopathic arthritis (JIA), open squares JIA follow-up after 12 months, X indicates our patient with JIA with acute exacerbation, and closed circles show healthy donors (HD). A p-value of <0.05 was considered significant.
Figure 2Proliferative measures in Juvenile Idiopathic Arthritis (JIA) patients. Ki67-expressing CD4+CD28+CD45RA+ T cells (A), T cell receptor excision circles (TRECs) (B), and relative telomere length (RTL) (C). Closed squares show patients with juvenile idiopathic arthritis (JIA), open squares JIA follow-up after 12 months, X indicates our patient with JIA with acute exacerbation, and closed circles show healthy donors (HD). A p-value of <0.05 was considered significant.
Intracellular cytokine production during acute exacerbation
| TNFα (percentage of CD4+CD45RA+) | 6.09 | 6.99±2.52 (6.37; 4.62 to 10.43) | 6.26±4.60 (4.47; 1.82 to 12.9) |
| IFNα (percentage of CD4+CD45RA+) | 19.63* | 2.77±1.24 (2.60; 1.15 to 4.39) | 4.04±2.21 (3.52; 1.39 to 7.49) |
| IL-2 (percentage of CD4+CD45RA+) | 53.74 | 37.63±31.49 (28.65; 5.53 to 81.25) | 14.68±9.79 (14.54; 3.12 to 28.56) |
| TNFα (percentage of CD4+CD45RO+) | 41.99* | 21.11±9.17 (21.18; 7.74 to 34.36) | 18.19±8.79 (15.38; 11.31 to 34.69) |
| IFNα (percentage of CD4+CD45RO+) | 41.23* | 10.05±4.09 (10.12; 4.52 to 14.46) | 13.30±6.07 (12.08; 8.21 to 24.21) |
| IL-2 (percentage of CD4+CD45RO+) | 79.77 | 50.09±30.69 (41.09; 15.65 to 90.03) | 31.01±22.65 (24.37; 8.56 to 60.41) |
| TNFα (percentage of CD8+CD45RA+) | 8.19 | 7.05±3.64 (6.40; 2.70 to 21.30) | 5.39±4.04 (4.35; 1.44 to 11.80) |
| IFNγ (percentage of CD8+CD45RA+) | 18.21 | 11.27±8.12 (8.19; 4.49 to 24.05) | 8.68±5.13 (6.86; 4.61 to 18.20) |
| IL-2 (percentage of CD8+CD45RA+) | 54.61* | 25.73±26.00 (16.35; 6.63 to 17.52) | 12.49±9.45 (8.44; 3.99 to 25.89) |
| TNFα (percentage of CD8+CD45RO+) | 68.22* | 24.04±10.02 (27.43; 11.44 to 33.10) | 22.98±9.35 (22.6; 12.27 to 35.64) |
| IFNγ (percentage of CD8+CD45RO+) | 83.67* | 28.26±19.57 (27.43; 2.63 to 50.26) | 34.77±17.44 (33.33; 9.14 to 61.50) |
| IL-2 (percentage of CD8+CD45RO+) | 73.48* | 34.82±15.52 (31.53; 17.52 to 58.08) | 23.84±22.63 (12.86; 4.58 to 60.27) |
Total counts ×103 cells/μL are given as mean±standard deviation (median; range). Values from our patient with JIA with acute exacerbation (patient 7) below or above the range found in the JIA group are indicated with *.
HD, healthy donors; IFN, interferon; IL, interleukin; JIA, juvenile idiopathic arthritis; TNF, tumor necrosis factor.